Who are ALIMTA plus Epirubicin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): cetuximab + cisplatin + vinorelbine, cytarabine and mitoxantrone, S-1 plus Cisplatin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/alimta-plus-epirubicin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

ALIMTA plus Epirubicin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ALIMTA plus Epirubicin (ALIMTA plus Epirubicin) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antineoplastic agents. Area: Oncology.

phase 1 Antineoplastic agents Topoisomerase I, Topoisomerase II Oncology Small molecule Live · refreshed every 30 min

Target snapshot

ALIMTA plus Epirubicin (ALIMTA plus Epirubicin) — Eli Lilly and Company. Topoisomerase I inhibitor

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
ALIMTA plus Epirubicin TARGET	ALIMTA plus Epirubicin	Eli Lilly and Company	phase 1	Antineoplastic agents	Topoisomerase I, Topoisomerase II
cetuximab + cisplatin + vinorelbine	cetuximab + cisplatin + vinorelbine	Merck KGaA, Darmstadt, Germany	phase 3	Antineoplastic agents	EGFR
cytarabine and mitoxantrone	cytarabine and mitoxantrone	Pfizer	phase 3	Antineoplastic agents
S-1 plus Cisplatin	S-1 plus Cisplatin	Taiho Pharmaceutical Co., Ltd.	phase 3	Antineoplastic agents	Thymidylate synthase, DNA

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antineoplastic agents class)

Asan Medical Center · 1 drug in this class
Central European Cooperative Oncology Group · 1 drug in this class
Croatian Cooperative Group for Clinical Research in Oncology · 1 drug in this class
Eli Lilly and Company · 1 drug in this class
Groupe Oncologie Radiotherapie Tete et Cou · 1 drug in this class
Merck KGaA, Darmstadt, Germany · 1 drug in this class
Pfizer · 1 drug in this class
Taiho Pharmaceutical Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ALIMTA plus Epirubicin — Competitive Intelligence Brief. https://druglandscape.com/ci/alimta-plus-epirubicin. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab